In addition, SLC16A3 might be associated with decreased CD8+ T‐cell infiltration and increased myeloid‐derived suppressor cells (MDSC) enrichment, indicating that targeting SLC16A3 may reverse the suppressive tumour microenvironment and enhance the efficacy of anti‐PD‐1 therapy [11, 15, 16]. Here, SLC16A3 is linked to neoplasm.